Clinical Trial Update: hATTR Polyneuropathy in Russia

View source ↗

Summary

AstraZeneca-sponsored clinical trial evaluating hereditary transthyretin amyloidosis with polyneuropathy in Russia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin Amyloidosis

Snippet

Sponsor: AstraZeneca | Conditions: Hereditary Transthyretin Amyloidosis | Status: COMPLETED